Advertisement
Canada markets close in 3 hours 11 minutes

  • S&P/TSX

    21,760.05
    -28.43 (-0.13%)
     

  • S&P 500

    5,464.61
    -4.69 (-0.09%)
     

  • DOW

    39,149.52
    +37.36 (+0.10%)
     

  • CAD/USD

    0.7300
    -0.0024 (-0.32%)
     

  • CRUDE OIL

    80.90
    +0.07 (+0.09%)
     

  • Bitcoin CAD

    84,143.03
    -40.60 (-0.05%)
     

  • CMC Crypto 200

    1,273.90
    -9.88 (-0.77%)
     

  • GOLD FUTURES

    2,310.90
    -19.90 (-0.85%)
     

  • RUSSELL 2000

    2,017.30
    -5.05 (-0.25%)
     

  • 10-Yr Bond

    4.3080
    +0.0700 (+1.65%)
     

  • NASDAQ

    17,735.74
    +18.08 (+0.10%)
     

  • VOLATILITY

    12.74
    -0.10 (-0.78%)
     

  • FTSE

    8,225.33
    -22.46 (-0.27%)
     

  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     

  • CAD/EUR

    0.6830
    -0.0002 (-0.03%)
     
MARKETS LIVE BLOG:

STOCKS SHED LOSSES AS INVESTORS ON WATCH FOR CUES

Rivian stock soars after Volkswagen says it'll invest up to US$5 billion in JV

Stocks in play: Cardiol Therapeutics Inc.

Baystreet.ca

Added another feather to its cap last week with the announcement of its Phase II MAvERIC-Pilot study topline results. The Canadian biotechnology company has captured investors’ attention this year with significant milestones achieved, including the advancement of two simultaneous Phase II clinical trials, granting of Orphan Drug Designation by the US FDA for its flagship drug CardiolRx™, and most recently, the announcement of positive topline results from their MAvERIC-Pilot study. Cardiol Therapeutics Inc. shares T.CRDL are trading down $0.04 at $3.24.

Read: